CD95 Polypeptides
JP2024541501APending Publication Date: 2024-11-08DEUTES KREBSFORSCHUNGSZENT STIFTUNG DES OFFENTLICHEN RECHTS +1
Patent Information
- Application Number
- JP2024531209
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-11-25
- Filing Date
- 2022-11-24
- Publication Date
- 2024-11-08
Smart Images

Figure 2024541501000001 
Figure 2024541501000002 
Figure 2024541501000003
Abstract
The present invention relates to an effector polypeptide comprising: (i) an amino acid sequence that is at least 70% identical to the amino acid sequence RSNLGWLCLLLLPIPLIVWVKRK (SEQ ID NO:1); and (ii) an amino acid substitution with a non-identical amino acid at at least one position selected from the group consisting of positions 1, 2, 3, 19, 22, and 23 of the amino acid sequence of (i). The present invention also relates to polynucleotides comprising nucleic acid sequences encoding said effector polypeptide, as well as related host cells, pharmaceutical compositions and uses, further related uses in the field of medicine, in particular in the treatment and / or prevention of cancer, inflammatory diseases, or acute or chronic neurodegenerative diseases.
Need to check novelty before this filing date? Find Prior Art
Citation Information
Patent Citations
Chimeric protein
JP2018512154A
Immunomodulatory fusion proteins and uses thereof
JP2020511136A
Immunomodulatory fusion proteins and uses thereof
WO2018170475A1
cell
WO2021205176A2
Compositions and methods for cellular immunotherapy
WO2022132836A2
